Oncternal Therapeutics Investor Relations Material
Latest events
Q2 2024
Oncternal Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Oncternal Therapeutics Inc
Access all reports
Oncternal Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies aimed at addressing cancers with critical unmet medical needs. Their diverse pipeline of treatments targets hematological malignancies and prostate cancer through multiple modalities. Their investigational product candidates include ONCT-808, an autologous CAR T cell therapy targeting ROR1 for patients with multiple hematologic and solid malignancies; ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI) for advanced prostate cancer; and Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein expressed in various malignancies. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Key slides for Oncternal Therapeutics Inc
Corporate Presentation
Oncternal Therapeutics Inc
Corporate Presentation
Oncternal Therapeutics Inc
Latest articles
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Irwin Jacobs & Andrew Viterbi: Qualcomm's Pioneering Founders
In 1985, Irwin Jacobs and Andrew Viterbi co-founded Qualcomm, a leading company in telecommunications and semiconductor innovation.
3 Oct 2024
Ticker symbol
ONCT
Country
🇺🇸 United States